China SXT Pharmaceuticals reported asset growth of 60.43% for the quarter ended Mar 2026. These growth metrics cover 16 quarters of results from Dec 2018 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Dec2018 | Mar2019 | Sep2019 | Mar2020 | Sep2020 | Mar2021 | Sep2021 | Mar2022 | Sep2022 | Mar2023 | Sep2023 | Mar2024 | Sep2024 | Mar2025 | Sep2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||||||||
| Assets Growth (1y) | 128.14% | 189.84% | 24.22% | 4.33% | 59.19% | -5.71% | -2.90% | -2.16% | -11.90% | -34.23% | -21.75% | 112.49% | -6.33% | -14.98% | 60.43% | |
| Assets Growth (3y) | 65.24% | 41.80% | 24.29% | -1.27% | 10.84% | -15.34% | -12.52% | 10.99% | -13.56% | 5.91% | 5.55% | |||||
| Assets Growth (5y) | 31.01% | 12.90% | 5.77% | 6.11% | -0.04% | 1.85% | 0.12% | |||||||||
| Capital Expenditures (QoQ)Capex (QoQ) | 286.65% | |||||||||||||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | 1,312.65% | 2,049.88% | -21.58% | 25.54% | 83.33% | -99.70% | 16.55% | 9,417.68% | 11.55% | 284.60% | -30.50% | 61.47% | 49.95% | 14.33% | 55.68% | |
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | 172.84% | -56.62% | 18.77% | -28.77% | 33.58% | 3.46% | -3.32% | 739.23% | 5.15% | 92.20% | 17.50% | |||||
| Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) | 92.46% | 97.29% | 5.37% | 17.55% | 19.96% | 15.38% | 16.10% | |||||||||
| Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) | -463.97% | |||||||||||||||
| Cash from Investing Activities (QoQ)Cash from Investing (QoQ) | 149.97% | |||||||||||||||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | 555.25% | |||||||||||||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | -163.18% | |||||||||||||||
| Free Cash Flow Growth (1y)FCF Growth (1y) | 757.84% | |||||||||||||||
| Free Cash Flow (QoQ)FCF (QoQ) | -192.34% | |||||||||||||||
| Net Cash Flow Growth (1y)NCF Growth (1y) | 888.39% | |||||||||||||||
| Net Cash Flow (QoQ)NCF (QoQ) | 1,399.71% | |||||||||||||||
| Net Income Growth (1y) | 0.21% | |||||||||||||||
| Net Income (QoQ) | -154.18% | |||||||||||||||
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 34.37% | 126.31% | 35.87% | -16.89% | -8.96% | -11.37% | -14.35% | -21.86% | -21.63% | -20.13% | -65.82% | -71.55% | -45.70% | -33.48% | -34.42% | |
| Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) | 18.45% | 18.57% | 1.94% | -16.82% | -15.14% | -17.91% | -38.78% | -43.80% | -47.41% | -46.74% | -50.44% | |||||
| Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) | 2.21% | 0.79% | -22.27% | -33.43% | -35.30% | -36.33% | -39.41% | |||||||||
| Total Debt Growth (1y) | -32.19% | 2,952.57% | 2,460.71% | -74.23% | -99.35% | -98.41% | -73.73% | 4,916.67% | 2,470.83% | -65.73% | 115.40% | 99.99% | 27.82% | 27.50% | 23.83% | |
| Total Debt Growth (3y) | -51.69% | -50.02% | -64.79% | -41.02% | -64.74% | -35.15% | 144.11% | 225.17% | 313.66% | -4.40% | 50.51% | |||||
| Total Debt Growth (5y) | -5.31% | 16.50% | 19.32% | -32.46% | -34.48% | -7.00% | 87.26% |
Pull China SXT Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=SXTC&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "SXTC", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=SXTC&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();